Back to Newsroom
Back to Newsroom

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of SPLK, NERV and KNDI

Monday, 11 January 2021 01:35 PM

The Klein Law Firm

Topic:
Lawsuits

NEW YORK, NY / ACCESSWIRE / January 11, 2021 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

Splunk Inc. (NASDAQ:SPLK)
Class Period: October 21, 2020 - December 2, 2020
Lead Plaintiff Deadline: February 2, 2021

During the class period, Splunk Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (1) Splunk was not closing deals with its largest customers in the third fiscal quarter of 2021; (2) Splunk was not hitting the financial targets it had previously announced; and (3) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in SPLK: http://www.kleinstocklaw.com/pslra-1/splunk-inc-loss-submission-form?id=12074&from=1

Minerva Neurosciences, Inc. (NASDAQ:NERV)
Class Period: May 15, 2017 - November 30, 2020
Lead Plaintiff Deadline: February 8, 2021

The NERV lawsuit alleges that Minerva Neurosciences, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in NERV: http://www.kleinstocklaw.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?id=12074&from=1

Kandi Technologies Group, Inc. (NASDAQ:KNDI)
Class Period: March 15, 2019 - November 27, 2020
Lead Plaintiff Deadline: February 9, 2021

Throughout the class period, Kandi Technologies Group, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Kandi artificially inflated its reported revenues through undisclosed related party transactions, or otherwise had relationships with key customers that indicated those customers did not have an arms length relationship with Kandi; (ii) the majority of Kandi's sales in the past year had been to undisclosed related parties and/or parties with such a close relationship and history with Kandi that it cast doubt on the arms-length nature of their relationship; (iii) all the foregoing, once revealed, was foreseeably likely to cast doubt on the validity of Kandi's reported revenues and, in turn, have a foreseeable negative impact on the Company's reputation and valuation; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in KNDI: http://www.kleinstocklaw.com/pslra-1/kandi-technologies-group-inc-loss-submission-form?id=12074&from=1

The Klein Law Firm, Monday, January 11, 2021, Press release picture

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
J. Klein, Esq.
Empire State Building
350 Fifth Avenue
59th Floor
New York, NY 10118
[email protected]
Telephone: (212) 616-4899
Fax: (347) 558-9665
www.kleinstocklaw.com

SOURCE: The Klein Law Firm

Topic:
Lawsuits
Back to newsroom
Back to Newsroom
Share by: